Cerity Partners LLC Raises Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cerity Partners LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 3.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 13,525 shares of the biopharmaceutical company’s stock after acquiring an additional 506 shares during the period. Cerity Partners LLC’s holdings in Alnylam Pharmaceuticals were worth $3,238,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ALNY. Larson Financial Group LLC grew its stake in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. R Squared Ltd bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $33,000. OFI Invest Asset Management purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $35,000. Versant Capital Management Inc boosted its stake in Alnylam Pharmaceuticals by 77.6% in the fourth quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 83 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 47 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ALNY. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a report on Monday, March 31st. They set a “buy” rating and a $353.00 price objective for the company. Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating for the company in a report on Friday. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $280.00 to $328.00 in a report on Monday, March 24th. Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday, March 21st. Finally, Scotiabank lifted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 31st. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $315.58.

Alnylam Pharmaceuticals Trading Up 0.9 %

Shares of Alnylam Pharmaceuticals stock opened at $240.01 on Tuesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a market cap of $31.22 billion, a P/E ratio of -110.60 and a beta of 0.30. The firm has a 50-day simple moving average of $252.47 and a two-hundred day simple moving average of $258.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company’s stock, valued at $3,240,344.36. The trade was a 10.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is owned by company insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.